AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Fatty Acid Amide Hydrolase (FAAH) Inhibitor - Pipeline Insight, 2019: Analysis by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com

February 27, 2019

DUBLIN--(BUSINESS WIRE)--Feb 27, 2019--The “Fatty Acid Amide Hydrolase (FAAH) Inhibitor - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Fatty Acid Amide Hydrolase (FAAH) Inhibitor - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Fatty Acid Amide Hydrolase (FAAH) Inhibitor development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

  • Provides a snapshot of the therapeutics pipeline activity for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
  • Features the Fatty Acid Amide Hydrolase (FAAH) Inhibitor pipeline across the complete product development cycle including all clinical and non-clinical stages
  • Offers detailed therapeutic product profiles of Fatty Acid Amide Hydrolase (FAAH) Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Fatty Acid Amide Hydrolase (FAAH) Inhibitor

Reasons to Buy

  • Establish a comprehensive understanding of the current pipeline scenario across Fatty Acid Amide Hydrolase (FAAH) Inhibitor to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Fatty Acid Amide Hydrolase (FAAH) Inhibitor research & development (R&D)
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify and understand the sought after therapy areas and indications for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
  • Identify the product attributes and use it for target finding, drug repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Fatty Acid Amide Hydrolase (FAAH) Inhibitor to enhance and expand business potential and scope
  • Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress

Companies Mentioned

  • Johnson & Johnson
  • Renovis
  • Vernalis
  • Pfizer
  • Janssen-Cilag
  • Sanofi-Aventis
  • Advinus Therapeutics

Topics Covered

1. Report Introduction

2. Fatty Acid Amide Hydrolase (FAAH) Inhibitor - Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor

4. Comparative Analysis

5. Fatty Acid Amide Hydrolase (FAAH) Inhibitor Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. Fatty Acid Amide Hydrolase (FAAH) Inhibitor Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/x4mh5d/fatty_acid_amide?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190227005699/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs,Enzymes

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/27/2019 11:42 AM/DISC: 02/27/2019 11:42 AM

http://www.businesswire.com/news/home/20190227005699/en